Minerva Neurosciences Inc... (NERV)
Minerva Neurosciences Inc. (NERV) Stock Price, Analysis & Data
| Bid | 3.19 |
| Market Cap | 187.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -394.35M |
| Beta | -0.11 |
| EPS (ttm) | -32.78 |
| PE Ratio (ttm) | n/a |
| Forward PE | -9.33 |
| P/B (ttm) | -0.68 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 5, 2025 |
| Ask | 5.41 |
| Volume | 138,129 |
| Avg. Volume (20D) | 225,700 |
| Open | 4.31 |
| Previous Close | 4.32 |
| Day's Range | 3.90 - 4.56 |
| 52-Week Range | 1.76 - 12.46 |
| Analyst | Hold |
| Price Target | 7.5 (91.33%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts....
Financial Performance
In 2025, Minerva Neurosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -293.42M, a decrease of -20,492.68%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for NERV stock is "Hold". The 12-month stock price forecast is 7.5, which is upside of 91.33% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
